Recalling P446. P4501A1 (CYP1A1) opting for clinical application

Drug Metabolism Reviews

Volumn 39, Issue 2-3, 2007, Pages 323-341

  Hildebrandt, Alfred G ^a   Schwarz, Dieter ^b   Krusekopf, Solveigh ^b   Kleeberg, Ullrich ^c   Roots, Ivar ^b  

^a Charité Universitätsmedizin Berlin ^*  (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Bundesamt fur Verbraucherschutz und Lebensmittelsicherheit   (Germany)

Author keywords

17 estradiol; Absolute spectra; Benzo a pyrene; CYP1A1; Cytochrome P450; Diolepoxide 2; Epoxidation; Extinction coefficients; Genetic polymorphism; Hyperforin; Methylcholanthrene; P446; P448; Phenobarbital; Spin state; St. John's wort

Indexed keywords

BENZO[A]PYRENE; CYTOCHROME P446; CYTOCHROME P448; CYTOCHROME P450 1A1; ESTRADIOL; ESTRONE; ICOSAPENTAENOIC ACID; UNCLASSIFIED DRUG;

DETOXIFICATION; ENZYME ANALYSIS; GENETIC VARIABILITY; HUMAN; NOMENCLATURE; NONHUMAN; REVIEW; SPECTROSCOPY;

ANIMALS; CYTOCHROME P-450 CYP1A1; HUMANS; ISOENZYMES; MICROSOMES, LIVER; NUTRITION PHYSIOLOGY; PHARMACOLOGY, CLINICAL; SPECTROPHOTOMETRY, ULTRAVIOLET; TERMINOLOGY; TOXICOLOGY;

EID: 34548379863     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602530701498026     Document Type: Review

References (72)

1. Alvares, A. P., Schilling, G., Levin, W., Kuntzman, R. (1967). Studies on the induction of CO-binding pigments in liver microsomes by phenobarbital and 3-methylcholanthrene. Biochem. Biophys. Res. Commun. 29:521-526.
2. 1-450 cDNA probe. Cytogenet. Cell Genet. 46:574-575.
3. Burke, M. D., Prough, R. A., Richard, T. (1977). Characteristics of a microsomal cytochrome P448 mediated reaction. Drug Metabol. Dispos. 5:1-8.
4. Cammer, W., Schenkman, J. B., Estabrook, R. W. (1966). EPR measurements of substrate interaction of cytochrome P-450. Biochem. Biophys. Res. Commun. 23:264-268.
5. Cascorbi, I., Brockmöller, J., Roots, I. (1996). A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res. 56:4965-4969.
6. Chernogolov, A., Behlke, J., Schunck, W.-H., Roots, I., Schwarz, D. (2003). Human CYP1A1 allelic variants: baculovirus expression and purification, hydrodynamic, spectral, and catalytical properties and their potency in the formation of all-trans-retinoic acid. Protein Expr. Purif. 28:259-269.
7. Conney, A. H. (2003). Induction of drug metabolizing enzymes: A path to the discovery of multiple cytochromes P450. Annu. Rev. Pharmacol. Toxicol. 43:1-30.
8. Conney, A. H., Lu, Y., Lou, Y., Xie, J., Huang, M. (1999). Inhibitory effect of green and black tea on tumor growth. Proc. Soc. Exp. Biol. Med. 220:229-233.
9. Crofts, F., Taioli, E., Trachman, J., Cosma, G. N., Curie, D., Toniolo, P., Garte, S. J. (1994). Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15:2961-2963.
10. Drakoulis, N., Cascorbi, I., Brockmöller, J., Gross, C. R., Roots, I. (1994). Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region. Clin. Investig. 72:240-248.
11. Estabrook, R. W. (1999). Discovering the functions of cytochrome P450 in drug metabolism: The role of Alfred Hildebrandt. Drug Metab. Rev. 31:317-331.
12. Estabrook, R. W. (2003). A passion for P450s (Remembrances of the early history of research on cytochrome P450). Drug Metab. Disposit. 31:1461-1473.
13. Estabrook, R. W., Cooper, D.Y., Rosenthal, O. (1963). The light-reversible carbon monoxide inhibition of the steroid C-21 hydroxylation system of the adrenal cortex. Biochem. Z. 338:741-755.
14. Estabrook, R. W., Peterson, J. A., Baron, J., Hildebrandt, A. G. (1972). The spectrophotometric measurement of turbid suspensions of cytochromes associated with drug metabolism. In: Methods in Pharmacology (Chignell, C. F., Ed.) Vol. 2, pp. 303-350, Appleton-Century-Crofts, New York.
15. Guengerich, F. P. (2004). Cytochrome P450: What have we learned and what are the future issues? Drug Metab. Rev. 36:159-197.
16. Guengerich, F. P. (1977). Separation and purification of multiple forms of microsomal cytochrome P-450. Activities of different forms of cytochrome P-450 towards several compounds of environmental interest. J. Biol. Chem. 252:3970-3979.
17. Hashimoto, Y., Yamano, T., Mason, H. S. (1962). An electron spin resonance study of microsomal electron transport. J. Biol. Chem. 237:3843-3844.
18. Haugen, D. A., Coon, M. J. (1976). Properties of electrophoretically homogeneous phenobarbital-inducible and β-naphthoflavone-inducible forms of liver microsomal cytochrome P-450. J. Biol. Chem. 251:7929-7939.
19. Hayashi, S., Watanabe, J., Nakachi, K., Kawajiri, K. (1991). Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J. Biochem. (Tokyo). 110:407-411.
20. Hildebrandt, A. (1965): Die beschleunigte Elimination von Sulfadimethoxin bei Hunden durch Phenobarbital. MD Thesis. Medical Faculty. University Tübingen (Germany).
21. Hildebrandt, A. G., Estabrook, R. W. (1969). Spectrophotometric studies of cytochrome P-450 of liver microsomes after induction with phenobarbital and 3-methylcholanthrene. (1969). In: Microsomes and Drug Oxidations (Gillette, J. R., Conney, A. H., Cosmides, G. J., Estabrook, R. W., Fouts, J. R., Mannering, G. J., eds.) pp. 331 -347, Academic Press Inc, New York.
22. Hildebrandt, A., Remmer, H., Estabrook, R. W. (1968). Cytochrome P-450 in liver microsomes - one pigment or many. Biochem. Biophys. Res. Commun. 30:607-612.
23. Huang, M. T., Wood, A. W., Chang, R. L., Yagi, H., Sayer, J. M., Jerina, D. M., Conney, A. H. (1986). Inhibitory effect of 3-hydroxybenzo(a)pyrene on the mutagenicity and tumorigenicity of (+/-)-7 beta, 8 alpha-dihydroxy-9 alpha, 10 alpha-epoxy-7,8,9,10 tetrahydrobenzo(a)pyrene. Cancer Res. 46:558-566.
24. Huang, C. S., Shen, C. Y., Chang, K. J., Hsu, S. M., Chern, H. D. (1999). Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Br. J. Cancer 80:1838-1843.
25. Ishibe, N., Hankinson, S. E., Colditz, G. A., Spiegelman, D., Willett, W. C., Speizer, F. E., Kelsey, K. T., Hunter, D. J. (1998) Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res. 58:667-671.
26. Jefcoate, C. R. E., Gaylor, J. L., Calabrese, R. L. (1969). Ligand interactions with cytochrome P-450. I. Binding of primary amines. Biochemistry 8:3455-3463.
27. Jefcoate, C. R. E., Gaylor, J. L. (1969). Ligand interaction with hemoprotein P-450. II. Influence of phenobarbital and methylcholanthrene induction processes on P-450 spectra. Biochemistry 8:3464-3471.
28. Kawajiri, K., Nakachi, K., Imai, K., Watanabe, J., Hayashi, S. (1993). The CYP1A1 gene and cancer susceptibility. Crit. Rev. Oncol. Hematol. 14:77-87.
29. Kawalek, J. C., Levin, W., Ryan, D., Thomas, P. E., Lu, A. Y. H. (1975) Purification of liver microsomal cytochrome P-448 from 3-methylcholanthrene- treated rabbits. Mol. Pharmacol. 11:874-878.
30. Kinoshita, T., Horie, S. (1967). Studies on P-450. 3. On the absorption spectrum of P-450 in rabbit liver microsomes. J. Biochem. (Tokyo) 61:26-34.
31. Kisselev, P., Schunck, W. H., Roots, I., Schwarz, D. (2005). Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. Cancer Res. 65:2972-2978.
32. Kisselev, P., Schwarz, D., Platt, K. L., Schunck, W. H., Roots, I. (2002). Epoxidation of benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1 in reconstituted membranes. Effects of charge and nonbilayer phase propensity of the membrane. Eur. J. Biochem. 269:1799-1805.
33. Koop, D. R., Morgan, E. T., Tarr, G. E., Coon, M. J. (1982). Purification and characterization of a unique isozyme of P-450 from liver microsomes of ethanol-treated rabbits. J. Biol. Chem. 257:8472-8480.
34. Krusekopf, S., Roots, I. (2005). St. John's wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways. Pharmacogenet. Genomics 15:817-829.
35. Krusekopf, S., Roots, I., Hildebrandt, A. G., Kleeberg, U. (2003). Time-dependent transcriptional induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by H+/K+-ATPase inhibitors and other xenobiotics. Xenobiotica 33:107-118.
36. Le Marchand, L., Murphy, S. P., Hankin, J. H., Wilkens, L. R., Kolonel, L. N. (2000). Intake of flavonoids and lung cancer. J. Natl. Cancer Inst. 92:154-160.
37. Lu, A. Y., Kuntzman, R., West, S., Jacobson, M., Conney, A. H. (1972). Reconstituted liver microsomal enzyme system that hydroxylates drugs, other foreign compounds, and endogenous substrates. II. Role of the cytochrome P-450 and P-448 fractions in drug and steroid hydroxylation. J. Biol. Chem. 247:1727-1734.
38. Mitrunen, K., Hirvonen, A. (2003). Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat. Res. 544:9-41.
39. Miyake, Y., Gaylor, J. L., Mason, H. S. (1968). Properties of a submicrosomal particle containing P-450 and flavoprotein. J. Biol. Chem. 243:5788-5797.
40. Miyoshi, Y., Noguchi, S. (2003). Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women. Biomed. Pharmacother. 57:471-481.
41. Miyoshi, Y., Takahashi, Y., Egawa, C., Noguchi, S. (2002). Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women. Breast J. 8:209-215.
42. Nachmansohn, D. (1979). Otto Heinrich Warburg. In: German-Jewish Pioneers in Science 1900-1933 (David Nachmansohn, Ed.) pp. 233-267, Springer-Verlag Berlin Heidelberg New York.
43. Nebert, D. W., Gelboin, H. V. (1968). Substrate-inducible microsomal aryl hydroxylase in mammalian cell culture. II. Cellular responses during enzyme induction. J. Biol. Chem. 243:6250-6261.
44. Nebert, D. W. (1970). Microsomal cytochromes b5 and P450 during induction of aryl hydrocarbon hydroxylase activity in mammalian cell culture. J. Biol. Chem. 245:515-527.
45. Nebert, D. W., Kon, H. (1973). Genetic regulation of aryl hydrocarbon hydroxylase induction V. Specific changes in spin state of cytochrome P450 from genetically responsive animals. J. Biol. Chem. 248:169-178.
46. Nelson, D. R., Koymans, L., Kamataki, T., Stegman, J. J., Feyereisen, F., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C., Nebert, D. W. (1996). P450 superfamily; update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-41.
47. Omura, T., Sato, R. (1964). The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 239:2370-2378.
48. Peisach, J., Blumberg, W.E. (1970). Electron paramagnetic resonance study of the high- and low-spin forms of cytochrome P-450 in liver and in liver microsomes from a methylcholanthrene-treated rabbit. Proc. Nat. Acad. Sci. 67:172-179.
49. Pickett, C. B., Remus, L., Jeter, J., Morin, J., Lu, A. Y. H. (1981). Electroimmunochemical quantification of cytochrome P-450, cytochrome P-448, and epoxide hydrolase in rat liver microsomes. J. Biol. Chem. 256:8815-8820.
50. Prough, R. A. (1999). Introduction: Basal and inducible expression of cytochromes P450 and related enzymes. The FASEB Journal 10:807-808.
51. Reichert, R., Remmer, H. (1964). Die Induktion mikrosomaler Cytochrome durch Pharmaka. Naunyn-Schmiedebergs Arch. Exp. Pharmakol. 247:374 (Abstract).
52. Remmer, H. (1959). Der beschleunigte Abbau von Pharmaka unter dem Einfluss von Luminal. Naunyn-Schmiedebergs Arch. Exp. Pharmakol. 235:279-290.
53. Remmer, H., Alsleben, B. (1958). Die Aktivierung der Entgiftung in den Lebermikrosomen während der Gewöhnung. Klin. Wochenschr. 36:332-333.
54. Remmer, H., Schenkman, J., Estabrook, R. W., Sasame, H., Gillette, J., Narasimhulu, S., Cooper, D. Y., Rosenthal, O. (1965). Drug interaction with hepatic cytochrome. Mol. Pharmacol. 2:187-190.
55. Saito, T., Strobel, H. W. (1981). Purification to homogeneity and characterization of a form of cytochrome P-450 with high specificity for benzo[?]pyrene from ?-naphtoflavone-pretreated rat liver microsomes. J. Biol. Chem. 256:984-988.
56. Sandhu, P., Guo, Z., Baba, T., Martin, M. V., Tukey, R. H., Guengerich, F. P. (1994). Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification, spectral characterization, and catalytic activities of the enzyme. Arch. Biochem. Biophys. 309:168-177.
57. Schenkman, J. B., Remmer, H., Estabrook, R. W. (1967). Spectral studies of drug interaction with hepatic microsomal cytochrome. Mol. Pharmacol. 3:113-123.
58. Schwarz, D., Kisselev, P., Cascorbi, I., Schunck, W. H., Roots, I. (2001). Differential metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8- dihydrodiol by human CYP1A1 variants. Carcinogenesis 22:453-459.
59. Schwarz, D., Kisselev, P., Chernogolov, A., Schunck, W. H., Roots I. (2005b). Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns. Biochem. Bioph. Res. Co. 336: 779-783.
60. Schwarz, D., Kisselev, P., Ericksen, S. S., Szklarz, G. D., Chernogolov, A., Honeck, H., Schunck, W. H., Roots, I. (2004). Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid. Biochem Pharmacol. 15:1445-1457.
61. Schwarz, D., Kisselev, P., Honeck, H., Cascorbi, I., Schunck, W. H., Roots, I. (2001b). Co-expression of human cytochrome P4501A1 (CYP1A1) variants and human NADPH-cytochrome P450 reductase in the baculovirus/insect cell system. Xenobiotica 31:345-356.
62. Schwarz, D., Kisselev, P., Roots, I. (2003). St. John's wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1. Cancer Res. 63:8062-8068.
63. Schwarz, D., Kisselev, P., Roots, I. (2005). CYP1A1 genotype-selective inhibition of benzo[a]pyrene activation by quercetin. Eur. J. Cancer 41:151-158.
64. Schwarz, D., Kisselev, P., Schunck, W.-H., Chernogolov, A., Boidol, W., Cascorbi, I., Roots, I. (2000). Allelic variants of human cytochrome P4501A1 (CYP1A1): effect of T4621N and 1462V substitutions on steroid hydroxylases specificity. Pharmacogenetics 10:519-530.
65. Schwarz, D., Roots, I. (2003). In vitro assessment of inhibition by natural polyphenols of metabolic activation of procarcinogens by human CYP1A1. Biochem. Biophys. Res. Commun. 303:902-907.
66. Sladek, N. E., Mannering, G. J., (1966). Evidence for a new P-450 hemoprotein in hepatic microsomes from methylcholanthrene treated rats. Biochem. Biophys. Res. Commun. 8:668-674.
67. Spurr, N. K., Gough, A. C., Stevenson, K., Wolf, C. R. (1987). Msp-1 polymorphism detected with a cDNA probe for the P-450 I family on chromosome 15. Nucleic Acids Res. 15:5901.
68. Szklarz, G. D., Paulsen, M. D. (2002). Molecular modeling of cytochrome P450 1A1: enzyme-substrate interactions and substrate binding affinities. J. Biomol. Struct. Dyn. 20:155-162.
69. Tsai, R., Yu, C. A., Gunsalus, I. C., Peisach, J., Blumberg, W., Orme-Johnson, W. H., Beinert, H. (1970). Spin-state changes in cytochrome P-450cam on binding of specific substrates. Proc. Nat. Acad. Sci. 66:1157-1163.
70. Wester, M. R., Johnson, E. F., Marques-Soares, C., Dansette, P. M., Mansuy, D., Stout, C. D. (2003). Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes. Biochemistry 42:6370-6379.
71. Williams, P. A., Cosme, J., Sridhar, V., Johnson, E. F., McRee, D. E. (2000). Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell 5:121-131.
72. Yang, K., Lamprecht, S. A., Liu, Y., Shinozaki, H., Fan, K., Leung, D., Newmark, H., Steele,V. E., Kelloff, G. J., Lipkin, M. (2000). Chemoprevention studies of the flavonoids quercetin and rutin in normal and azoxymethane-treated mouse colon. Carcinogenesis 21:1655-1660.